Jonathan Allan Sells 4,628 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 4,628 shares of the business’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $145,041.52. Following the transaction, the general counsel directly owned 28,836 shares in the company, valued at $903,720.24. This trade represents a 13.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jonathan Allan also recently made the following trade(s):

• On Tuesday, March 17th, Jonathan Allan sold 4,267 shares of Stoke Therapeutics stock. The shares were sold at an average price of $33.01, for a total transaction of $140,853.67.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $33.51 on Friday. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of 50.01 and a beta of 1.07. The company’s fifty day moving average is $32.61 and its two-hundred day moving average is $30.02. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $40.22.

Key Stories Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

Institutional Trading of Stoke Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Kestra Advisory Services LLC bought a new position in shares of Stoke Therapeutics during the 4th quarter worth approximately $26,000. Harbour Investments Inc. increased its holdings in shares of Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after acquiring an additional 898 shares during the last quarter. Generali Investments Management Co LLC bought a new stake in Stoke Therapeutics in the 3rd quarter valued at $41,000. BNP Paribas Financial Markets lifted its holdings in Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after purchasing an additional 1,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares during the period.

Analyst Ratings Changes

Several brokerages recently issued reports on STOK. HC Wainwright boosted their price target on Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Canaccord Genuity Group raised their price objective on Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday. Loop Capital set a $35.00 price objective on Stoke Therapeutics in a report on Monday, January 5th. Wolfe Research initiated coverage on Stoke Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price objective on the stock. Finally, Needham & Company LLC upped their target price on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $41.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.